ERAS Erasca, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1761918 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-141.2%
TTM EPS YoY-125.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-48.7%
ROA-43.4%
ROIC (approx.)-48.1%
Asset turnover—
Leverage & solvency
Liabilities / assets8.2%
Debt / equity0.00x
Current ratio14.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-28.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $92.85M | $115.36M |
| SG&A expense | $38.55M | $41.73M |
| Operating income | -$140.91M | -$179.59M |
| Pretax income | -$124.55M | -$161.65M |
| Income tax | $0 | $0 |
| Net income | -$124.55M | -$161.65M |
| EBITDA | -$137.80M | -$175.78M |
| EPS (basic) | -0.44 | -0.69 |
| EPS (diluted) | -0.44 | -0.69 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 283.53M | 233.82M |
| Balance sheet | ||
| Cash & equivalents | $73.81M | $67.74M |
| Short-term investments | $202.27M | $230.57M |
| Current assets | $286.24M | $308.79M |
| PP&E, net | $13.30M | $16.32M |
| Total assets | $396.15M | $502.53M |
| Current liabilities | $28.51M | $31.39M |
| Total liabilities | $70.98M | $79.03M |
| Shareholders' equity | $325.17M | $423.50M |
| Shares outstanding | 284.16M | 283.22M |
| Cash flow statement | ||
| Operating cash flow | -$95.45M | -$109.42M |
| Capital expenditure | $128,000 | $60,000 |
| Free cash flow | -$95.58M | -$109.48M |
| Investing cash flow | $100.42M | -$156.62M |
| Financing cash flow | $1.10M | $240.70M |
| Depreciation & amortization | $3.11M | $3.81M |
| Stock-based compensation | $24.90M | $26.97M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.